|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cancer Genome Atlas Research Network.
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis
C, Wheeler DA, Murray BA, Schmidt L, et al: Comprehensive molecular
characterization of papillary renal cell carcinoma. N Engl J Med.
374:135–145. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gainor JF, Dardaei L, Yoda S, Friboulet L,
Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K,
Singh M, et al: Molecular mechanisms of resistance to first- and
second-generation ALK inhibitors in ALK-rearranged lung cancer.
Cancer Discov. 6:1118–1133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pal SK, Sonpavde G, Agarwal N, Vogelzang
NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman
RB, et al: Evolution of circulating tumor DNA profile from
first-line to subsequent therapy in metastatic renal cell
carcinoma. Eur Urol. 72:557–564. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Weinstein LS, Liu J, Sakamoto A, Xie T and
Chen M: Minireview: GNAS: Normal and abnormal functions.
Endocrinology. 145:5459–5464. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Furukawa T, Kuboki Y, Tanji E, Yoshida S,
Hatori T, Yamamoto M, Shibata N, Shimizu K, Kamatani N and
Shiratori K: Whole-exome sequencing uncovers frequent GNAS
mutations in intraductal papillary mucinous neoplasms of the
pancreas. Sci Rep. 1(161)2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fan C, Zhao C, Wang F, Li S and Wang J:
Significance of PTEN mutation in cellular process, prognosis, and
drug selection in clear cell renal cell carcinoma. Front Oncol.
9(357)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Que WC, Qiu HQ, Cheng Y, Liu MB and Wu CY:
PTEN in kidney cancer: A review and meta-analysis. Clin Chim Acta.
480:92–98. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sun B, Chen L, Fu H, Guo L, Guo H and
Zhang N: Upregulation of RICTOR gene transcription by the
proinflammatory cytokines through NF-κB pathway contributes to the
metastasis of renal cell carcinoma. Tumor Biol. 37:4457–4466.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Massari F, Ciccarese C, Santoni M,
Lopez-Beltran A, Scarpelli M, Montironi R and Cheng L: Targeting
fibroblast growth factor receptor (FGFR) pathway in renal cell
carcinoma. Expert Rev Anticancer Ther. 15:1367–1369.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pal SK, He M, Tong T, Wu H, Liu X, Lau C,
Wang JH, Warden C, Wu X, Signoretti S, et al: RNA-seq reveals
aurora kinase-driven mTOR pathway activation in patients with
sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res.
13:130–137. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Osanto S and van der Hulle T: Cabozantinib
in the treatment of advanced renal cell carcinoma in adults
following prior vascular endothelial growth factor targeted
therapy: Clinical trial evidence and experience. Ther Adv Urol.
10:109–123. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu X, Shen T, Mooers BHM, Hilberg F and
Wu J: Drug resistance profiles of mutations in the RET kinase
domain. Br J Pharmacol. 175:3504–3515. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bahcall M, Sim T, Paweletz CP, Patel JD,
Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, et al:
Acquired METD1228V mutation and resistance to MET inhibition in
lung cancer. Cancer Discov. 6:1334–1341. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lu T and Li J: Clinical applications of
urinary cell-free DNA in cancer: Current insights and promising
future. Am J Cancer Res. 7:2318–2332. 2017.PubMed/NCBI
|
|
19
|
Reckamp KL, Melnikova VO, Karlovich C,
Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K,
Croucher P, et al: A highly sensitive and quantitative test
platform for detection of NSCLC EGFR mutations in urine and plasma.
J Thorac Oncol. 11:1690–1700. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fujii T, Barzi A, Sartore-Bianchi A,
Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V,
Tsimberidou AM, Huang HJ, et al: Mutation-enrichment
next-generation sequencing for quantitative detection of KRAS
mutations in urine cell-free DNA from patients with advanced
cancers. Clin Cancer Res. 23:3657–3666. 2017.PubMed/NCBI View Article : Google Scholar
|
